NCT04776642 Biobank for "Arrhythmia and Conduction Disorders: TowArd Pathophysiology Based Treatment"
| NCT ID | NCT04776642 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Condition | Arrythmia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2014-12-18 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2014-12-18 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The 'ADAPT' Biobank is a collection of body material and data from patients with or at risk of cardiac arrhythmias who underwent or will undergo (non-) invasive treatment for this disease. Its main objective is to obtain a comprehensive collection of patient information and material to facilitate research and gain better insight into the complex pathophysiology of the different arrhythmias, the multifactorial process, the heterogeneity in clinical presentation, and prognosis. Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
Eligibility Criteria
Inclusion criteria: * Patients visiting the AMC outpatient clinic * Patients included in an ongoing clinical trial linked to this biobank. Studies are listed under point "Groups and interventions" and include: * MARK AF * INDICO AF * PREDICT AF * WEIGHTLOSS AF * MAD AF * Patients included in future clinical trial linked to this biobank. Studies may be linked to this biobank that investigates prevalent or incident cardiac arrhythmias. * Cardiac arrhtymias are defined as * Supraventricular tachycardia, among which the most common are: * Atrial Fibrillation (AF) * Atrial Tachycardia (AT) * Atrial Flutter (AFL) * Atrioventricular Nodal Reentrant Tachycardia (AVNRT) * Atrioventricular Reentrant Tachycardia (AVRT) * Ventricular tachycardia, among which the most common are: * Ventricular Tachycardia (VT) * Ventricular Flutter (VFL) * Ventricular Fibrillation (VF) * Bradycardia: * Sinus Node Dysfunction * AV Node Dysfunction * Interventricular Conduction Disorder * Arrhythmogenic cardiomyopathies, among which the most common are: * Dilated Cardiomyopathy * Restrictive Cardiomyopathy * Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Exclusion criteria (shared for all studies): * Age \< 18 * Unable or unwilling to comply with study procedures * Pregnancy or of childbearing potential without adequate contraception * NYHA class IV heart failure symptoms or left ventricular ejection fraction \<35%.
Contact & Investigator
Joris de Groot, MD, PhD
PRINCIPAL INVESTIGATOR
Amsterdam UMC - AMC
Frequently Asked Questions
Who can join the NCT04776642 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Arrythmia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04776642 currently recruiting?
Yes, NCT04776642 is actively recruiting participants. Contact the research team at e.l.hulsman@amsterdamumc.nl for enrollment information.
Where is the NCT04776642 trial being conducted?
This trial is being conducted at Amsterdam, Netherlands.
Who is sponsoring the NCT04776642 clinical trial?
NCT04776642 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). The principal investigator is Joris de Groot, MD, PhD at Amsterdam UMC - AMC. The trial plans to enroll 1,000 participants.